- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
- Interventions
- PF-07202954 Repeat Dose, PF-07202954 Single Dose, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–79
of 79
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fatty Liver, Non-Alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses
- Interventions
- Aramchol
- Drug
- Lead sponsor
- Galmed Research and Development, Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 17
- States / cities
- Chula Vista, California • Los Angeles, California • Pasadena, California + 12 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 81
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more
- Conditions
- Non-alcoholic Steatohepatitis, Fibrosis, Liver Diseases
- Interventions
- Emricasan (5 mg), Emricasan (50 mg), Placebo
- Drug
- Lead sponsor
- Conatus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 63 more
- Conditions
- Nonalcoholic Steatohepatitis, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease
- Interventions
- Cenicriviroc
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 41
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
- Interventions
- Placebo, PF-06865571, PF-05221304
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 184
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more
- Conditions
- Non Alcoholic Fatty Liver Diseases (NAFLD)
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona